11/9
Inconc.
Late treatment study
et al., Annals of the American Thoracic Society, doi:10.1513/AnnalsATS.202008-940OC (Peer Reviewed)
Hydroxych loroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial
Small early terminated very late stage (86% on oxygen, 44% enrolled in the ICU) RCT comparing HC Q vs. AZ, not finding a significant difference between the two treatments. There is no comparison with a control group. HC Q patients not in the ICU at enrollment (slightly earlier treatment) did better, OR 0.95 vs. 1.13.HC Q dosage is relatively low:Dose in first 24 hours - 1g (compare to Boulware et al. 2g)
Dose in 5 days - 2.4g (compare to Boulware et al. 3.8g)
Dose in 5 days - 2.4g (compare to Boulware et al. 3.8g)